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roximal Embolic Protection
“Game Changer” for Carotid Stents*
hristopher J. White, MD
ew Orleans, Louisiana
n this issue of the Journal, Stabile et al. (1) report a 30-day
troke and death rate of 1.4% in a single-center registry of
,300 patients after carotid artery stenting (CAS) using
roximal endovascular occlusion (PEO) with independent
eurological assessment. They found a higher risk for
ymptomatic versus asymptomatic patients (3.0% vs. 0.8%;
 0.05) and for high surgical risk compared with average
urgical risk patients (1.9% vs. 1.1%; p  0.05). The CAS
isk for patients age 80 years was not different than for
ounger patients. Only 4 patients (0.3%) were unable to
olerate proximal occlusion to complete the CAS procedure,
hereas approximately 1 in 5 patients experienced partial
ntolerance to PEO, which still allowed completion of the
rocedure with uninterrupted proximal protection. Inde-
endently, predictors of adverse outcome were lack of CAS
xperience, the presence of a symptomatic lesion, and the
bsence of clinical hypertension.
See page 1661
So why is this remarkable result a “game changer” for the
ractice of CAS? There is consensus among knowledgeable
xperts that CAS is a reasonable alternative to open surgery
carotid endarterectomy [CEA]) for stroke prevention when
erformed within the standards set by the Stroke Council of
he American Heart Association for 30-day stroke and
eath complication rates (2,3). These safety recommenda-
ions, codified in a 1998 expert consensus document (4),
ere based on the early randomized CEA trials and were
ecently updated in 2006 (3). Pursuant to these guidelines,
evascularization to prevent stroke is recommended for
symptomatic patients with carotid stenosis (60% to 99%)
ho are expected to live 5 years if the perioperative
30-day) stroke and death rate was 3%. For symptomatic
atients, revascularization is recommended for symptomatic
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiovascular Diseases, Ochsner Clinic Foundation,t
ew Orleans, Louisiana. Dr. White is a principal investigator for CABANA, a
ost-market surveillance trial of carotid stenting, sponsored by Boston Scientific.arotid stenosis (50% to 99%) if the 30-day stroke and death
isk is 6%.
Attempts to improve the safety of CAS have focused on
echanisms to reduce procedure-related atheroembolism
nd periprocedural stroke. Most importantly, we must
mprove patient selection and avoid performing CAS in
atients at highest risk for complications (Table 1) (5).
ocusing on the prevention of cerebral atheroemboli is a
ajor priority. A variety of embolic protection devices
EPDs) have been developed to address this issue, includ-
ng: 1) a distal occlusion balloon; 2) distal filter devices; and
) proximal protection devices with and without flow
eversal (Table 2). Surprisingly, there have been no random-
zed trials to demonstrate the safety and efficacy of any
arotid EPD, although 1 early meta-analysis concluded that
PDs did reduce the risk of stroke with CAS; this was a
ollection of early heterogeneous data (6).
The lack of proven efficacy of carotid EPDs to reduce
linical events is problematic because there are complica-
ions related to their use (7–9). The first carotid EPD was
distal occlusion balloon (PercuSurge Guardwire,
edtronic, Minneapolis, Minnesota), which was encum-
ered by occasional patient intolerance to interruption of
erebral blood flow, the inability to angiographically visual-
ze the lesion during stent deployment, and the fact that
theroemboli could still reach the brain via external carotid
ollaterals or after incomplete aspiration at the completion
f the procedure (10). The emergence of distal filter-type
PDs (Table 2) rapidly replaced the distal occlusion balloon
ecause they were much easier to use, did not occlude
erebral blood flow, and were well tolerated by patients.
ilter EPDs allowed the interventionalist to visualize target
esions during stent deployment. Further, filters are small,
uidewire-like devices that are compatible with conven-
ional CAS equipment.
Filters, traditionally easier to use by less experienced
perators, are only “partially” protective, allowing particles
maller than their pore sizes to pass through them and to the
rain. Although clinicians eagerly adopted filters on the
asis of their performance in saphenous vein grafts, there
as never been any comparative demonstration of their
rotective efficacy in the cerebral circulation. It is possible
hat small particles passing through the filters are harmful to
atients. Filters can occasionally be difficult to retrieve, and
filter can become so full that the overflowing debris must
e removed or aspirated separately to avoid spilling the
ontents of the filter during retrieval (11,12).
Theoretically, proximal protection systems should be
ore effective at preventing embolization than filters. The
EO is placed and functioning before the lesion is crossed
ith the operator’s choice of guidewire. PEOs are the only
evices that offer this safety feature. All distal EPDs require
hat the carotid lesion be crossed without emboli protection.
linicians have not enthusiastically adopted PEOs becausehe devices are relatively bulky and complicated to use. One
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April 20, 2010:1668–70 Proximal Embolic Protectionf the PEO systems (Gore Flow Reversal; Gore, Flagstaff,
rizona) uses active flow reversal and requires additional
enous access (13). The PEOs share similar drawbacks
ssociated with carotid flow occlusion as with the distal
alloon EPD. Approximately 5% to 10% patients will have
ome level of intolerance during the procedure, making it
ore difficult for the operator to manage the patient, and
he operator cannot angiographically visualize the target
esion during stent deployment. The increase in device
omplexity has discouraged interventionalists from widely
dopting PEO technology.
Comparing EPDs without head-to-head comparisons
as been inconclusive. Two noninvasive techniques (trans-
ranial Doppler [TCD] and diffusion-weighted imaging
DWI]) offer the ability to measure surrogate markers of
theroembolism to assess EPDs. TCD measures cerebral
mbolic signals (ESs). Clearly not all ESs are emboli, some
eing caused by turbulent flow and contrast injections, but
rough correlation exists between quantitative ES and the
isk of neuro-embolic events, making ES a reasonable
urrogate marker for embolic events related to CAS (14).
he other advantage of TCD is temporal resolution over
vent detection. We can determine whether there are more
Ss during stent deployment, pre-dilation, or post-dilation
han other phases of the CAS procedure (10). Quantita-
ively, it can be shown that fewer ESs occur with an EPD in
lace than without (10). TCD has shown ESs occurring
hroughout the procedure with a filter EPD in place,
hereas there were no ESs when the PEO flow reversal
ystem was used (15). However, ESs were detected during
nsertion and removal of the PEO device.
Magnetic resonance DWI may also be used to detect new
mbolic brain lesions after CEA and CAS (16). Most DWI
tudies agree with TCD studies, showing that there are
ewer new brain lesions after CEA when compared with
AS (17), although, when all cerebral complications are
ncluded, there is no difference between CEA or CAS
16,18). The majority of new DWI lesions are asymptom-
tic, and approximately half of them will disappear over
everal months, making their clinical importance uncertain
19). To date, studies have failed to confirm any correlation
ith new DWI lesions and neuropsychiatric function (16).
WI showed a reduction in new lesions when a filter EPD
as used during CAS as compared with no EPD (16).
hen comparing a distal balloon occlusion EPD with a
lter device during CAS, no difference was found between
ncreased Risk for Carotid Stent PlacementTable 1 Increased Risk for Carotid Stent Placement
Clinical Comorbidities Anatomical Features
Dementia Excessive arch vessel or carotid artery
tortuosity and lesion angulation
Prior disabling stroke Excessive aortic arch plaque burden
Multiple lacunar infarcts Heavily calcified arch or carotid vessels
Intracranial microangiopathy Difficult femoral vascular accesstdapted from Roubin et al. (5).he devices, with new cerebral lesions detected in 40% of
oth groups (20).
New DWI lesions are correlated with difficult to cannu-
ate aortic arch vessels, more contrast usage, and longer
uoroscopic times during diagnostic cerebral angiography
21). New brain lesions detected by DWI after CAS are
orrelated with difficult arch morphology (type III) and
omplex atherosclerotic arch lesions by transesophageal
chocardiography (complex 5 mm or mobile debris) (22).
he appearance of new embolic lesions in a hemisphere not
psilateral to the CAS procedure is compelling evidence that
ome cerebral emboli are caused by catheter manipulation in
he aortic arch. In clinical trials, approximately 20% of
linical embolic events associated with CAS occur in the
ontralateral cerebral circulation, which would not be ex-
ected to improve with PEO (23,24).
The message from this single-center European registry of
AS with a PEO device (1) seems clear. Proximal protec-
ion, in experienced hands, is associated with a dramatic
eduction in the expected 30-day stroke and death rate
ompared with other CAS registry reports (2). In these
xperienced interventionalists’ hands, the incidence of fem-
ral access complications was quite low for this 8- and 10-F
ystem, and the rapidity with which they were able to
omplete the CAS procedure resulted in1% of all patients
nable to tolerate proximal occlusion.
If the results of Stabile et al. (1) are reproducible, the
trategy of adopting PEO devices for CAS will be a true
ame changer. Proximal protection will become the pre-
erred mode of emboli protection used with CAS, and CAS
ill become the dominant revascularization procedure em-
loyed to prevent stroke. A percutaneous procedure with a
% perioperative stroke and death rate for symptomatic
atients and 1% for asymptomatic patients that avoids the
ignificant morbidity of open-neck surgery (myocardial
nfarction, cranial nerve palsy, wound infection, and hema-
arotid Embolic Protection DevicesTable 2 Carotid Embolic Protection Devices
Carotid Embolic Protection Device Manufacturer
Distal occlusion balloon
Percusurge Guardwire Medtronic, Minneapolis, Minneapolis
Distal filter devices
AccuNet Abbott Vascular, Abbott Park, Illinois
AngioGuard Cordis, Miami Lakes, Florida
FilterWire Boston Scientific, Natick, Massachusetts
Emboshield Abbott Vascular, Abbott Park, Illinois
Spider ev3, Plymouth, Minneapolis
Interceptor Medtronic, Minneapolis, Minneapolis
Rubicon Rubicon Medical, Salt Lake City, Utah
FiberNet Lumen Biomedical, Plymouth, Minneapolis
Proximal endovascular occlusion
Mo.Ma Invatec, Roncadelle, Italy
Gore W.L. Gore & Associates, Flagstaff, Arizonaoma) would be just what the doctor ordered.
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